Centogene, which provides genetic testing and rare
disease diagnostic products, filed on Friday with the SEC to raise up
to $69 million in an initial public offering.
The Rostock, Germany-based company was founded in 2006 and booked $50
million in sales for the 12 months ended June 30, 2019. It plans to
list on the Nasdaq under the symbol CNTG. SVB Leerink, Evercore ISI, Baird and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.